Oncology: Bladder
Saturday, May 16
IP41-01: Is There Still a Role for Ureteral Frozen Section Analysis During Radical Cystectomy? A Single-Center Retrospective Analysis
IP41-02: Beyond Smoking Status: Cumulative Exposure and Cessation Time Drive Perioperative Morbidity After Robot-Assisted Radical Cystectomy
IP41-03: A comparative analysis of da Vinci vs. hinotori surgical robotic systems for perioperative outcomes of robot-assisted radical cystectomy: a propensity score-matched analysis.
IP41-04: The Optimal Extent of Lymph Node Dissection in Patients with Bladder Squamous Cell Carcinoma: A Population-Based Study
IP41-05: Open Radical Cystectomy Achieves Perioperative Transfusion Rates Comparable to Robotic-assisted Radical Cystectomy – Real-World Evidence from a High-Volume Specialist Centre
IP41-06: Urodynamic and Functional Outcomes After ?-Shaped Versus Y-Shaped Robotic Intracorporeal Orthotopic Neobladder Reconstruction
IP41-07: IMPACT OF THE ILEAL WIDTH TO THE CAPACITY OF THE ORTHOTOPIC NEOBLADDER: THE AADAPT FORMULA IN CLINICAL PRACTICE
IP41-08: Patient-Reported Recovery Trajectories Following Radical Cystectomy: Findings from the UW Prospective Bounceback Cohort Study
IP41-09: The Use of ctDNA From Paired Blood and Urine to Predict Recurrence After Extirpative Surgery for the Treatment of Urothelial Carcinoma
IP41-10: Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoring. A systematic review and meta-analysis
IP41-11: Survival After Radical Cystectomy with Ureterocutaneostomy Exceeds Charlson Comorbidity Index Predictions: Implications for Urinary Diversion Selection
IP41-12: Feasibility, Acceptability, and Preliminary Impact of the MORE Program to Support Ostomy Care Among Bladder and Colorectal Cancer Patients and Caregivers
IP41-13: Can early removal of ureteral stent after Bricker ileal conduit provide less complications? An observational study in a high-volume centre.
IP41-14: Efficacy and Safety of Split-Dose Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Real-World Clinical Study
IP41-15: Clinical outcomes of neoadjuvant chemotherapy–guided bladder preservation in muscle-invasive bladder cancer: Long-term results of a phase II trial.
IP41-16: A Tumor-Agnostic ctDNA Approach for Muscle-Invasive Bladder Cancer: Clinical Applicability After Radical Cystectomy
IP41-17: Impact of Neoadjuvant Therapy on Oncologic Outcomes in Patients With Undetectable Pre-Cystectomy Circulating Tumor DNA
IP41-18: Impact of histologic variants on nodal involvement, lymphadenectomy outcomes, and survival after radical cystectomy for bladder cancer.
IP41-19: Simulating the Impact of Adjuvant Immunotherapy in the NIAGARA Trial Using Gated Counterfactual Survival Modeling
IP41-20: Outcomes of Neoadjuvant Chemotherapy in Patients with MIBC Who Progressed from NMIBC: Results from International Radical Cystectomy Consortium (IRCC)
IP41-21: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer
IP41-22: Neoadjuvant therapy in variant histology urothelial carcinoma undergoing radical cystectomy: A retrospective cohort from a Latin American cancer center
IP41-23: The impact of variant histology on oncologic outcomes in patients with node positive bladder cancer treated with radical cystectomy: a single-institution experience
IP41-25: Clinical outcomes in patients with pT0 bladder cancer treated with radical surgery: a multicenter retrospective study in Japan
IP41-26: Immunohistochemical Profiling of Glucose-regulated Protein 94 (GRP94) Reveals Its Prognostic Power in Predicting Progression-free Survival of Muscle-Invasive Bladder Cancer Patients
IP41-27: Evaluation of the MODAPLEX multiplex mRNA assay in muscle-invasive bladder cancer: comparison of responders and non-responders after neoadjuvant gemcitabine/cisplatin therapy
IP41-28: Disitamab Vedotin plus BCG intravesical instillation in patients with HER2 high expression high-risk non-muscle invasive bladder cancer(HR-NMIBC): efficacy and safety results from the phrase II Formula-01 trial
IP41-29: Molecular profiling of therapy-associated targets in metastatic urothelial carcinoma using the MODAPLEX platform: a step toward precision oncology
IP41-30: Circulating Basophils as a Novel Predictive Biomarker of Neoadjuvant Chemotherapy Response and Overall Survival in Patients Undergoing Radical Cystectomy for Bladder Cancer
Registered attendees
Yakov Klugman
Medical StudentRoswell Park Comprehensive Cancer Center